Drug intelligence / Profile preview

LT-301

Development stage: Preclinical
Lead developer: Chengdu Lingtai Krypton Biotechnology
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

LT-301 is a preclinical-stage lncRNA-based small nucleic acid therapeutic being developed by Chengdu Lingtai Krypton Biotechnology for the treatment of central nervous system (CNS) disorders, specifically Alzheimer's disease. The therapeutic utilizes the company's proprietary cross-blood-brain barrier (BBB) delivery platform, which leverages long non-coding RNA (lncRNA) functional modules to achieve efficient and targeted delivery across the blood-brain barrier into various brain regions.

Beyond the preview

Go deeper on LT-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LT-301.